VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | Novel agents for consolidation after auto-SCT in myeloma

Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, gives an overview of novel agents for consolidation after autologous stem cell transplantation (auto-SCT) for patients with myeloma. Dr Gagelmann highlights data from a study investigating lenalidomide, dexamethasone and bortezomib, and data from a study investigating quadruplet therapy with daratumumab and an immunomodulatory drug, commenting on the need for longer follow-up. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter